SMT201600198B - Derivati di 1,2,4-triazina-4-ammina - Google Patents
Derivati di 1,2,4-triazina-4-amminaInfo
- Publication number
- SMT201600198B SMT201600198B SM201600198T SM201600198T SMT201600198B SM T201600198 B SMT201600198 B SM T201600198B SM 201600198 T SM201600198 T SM 201600198T SM 201600198 T SM201600198 T SM 201600198T SM T201600198 B SMT201600198 B SM T201600198B
- Authority
- SM
- San Marino
- Prior art keywords
- triazine
- amine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30206010P | 2010-02-05 | 2010-02-05 | |
US38176410P | 2010-09-10 | 2010-09-10 | |
PCT/EP2011/051755 WO2011095625A1 (en) | 2010-02-05 | 2011-02-07 | 1,2,4-triazine-4-amine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201600198B true SMT201600198B (it) | 2016-08-31 |
Family
ID=43837724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201600198T SMT201600198B (it) | 2010-02-05 | 2016-06-23 | Derivati di 1,2,4-triazina-4-ammina |
Country Status (24)
Country | Link |
---|---|
US (6) | US8809525B2 (it) |
EP (1) | EP2531492B1 (it) |
JP (1) | JP5914361B2 (it) |
KR (2) | KR101838093B1 (it) |
CN (1) | CN102822150B (it) |
AU (1) | AU2011212430B2 (it) |
BR (1) | BR112012019540B1 (it) |
CA (1) | CA2789279C (it) |
CY (1) | CY1117780T1 (it) |
DK (1) | DK2531492T3 (it) |
ES (1) | ES2579949T3 (it) |
HR (1) | HRP20160636T1 (it) |
HU (1) | HUE028640T2 (it) |
IL (1) | IL221160A (it) |
MX (1) | MX352415B (it) |
MY (1) | MY180024A (it) |
PL (1) | PL2531492T3 (it) |
PT (1) | PT2531492T (it) |
RU (1) | RU2625791C2 (it) |
SG (1) | SG183146A1 (it) |
SI (1) | SI2531492T1 (it) |
SM (1) | SMT201600198B (it) |
WO (1) | WO2011095625A1 (it) |
ZA (1) | ZA201205788B (it) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2531492T3 (en) * | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-amine derivatives |
JP6263773B2 (ja) | 2011-02-23 | 2018-01-24 | マサチューセッツ インスティテュート オブ テクノロジー | 水溶性膜タンパク質およびその調製および使用方法 |
CN104341386A (zh) * | 2013-07-23 | 2015-02-11 | 中国科学院上海药物研究所 | 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途 |
US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
US10184794B2 (en) * | 2015-07-01 | 2019-01-22 | Makita Corporation | Laser marker |
CN108884061B (zh) * | 2017-01-13 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 |
CN108467386B (zh) * | 2017-02-23 | 2020-11-17 | 江苏恒瑞医药股份有限公司 | 稠杂芳基取代的1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 |
WO2018166493A1 (zh) | 2017-03-16 | 2018-09-20 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
CR20190593A (es) | 2017-06-22 | 2020-05-10 | Novartis Ag | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas |
BR112020000962A2 (pt) | 2017-07-18 | 2020-07-14 | Nuvation Bio Inc. | compostos de 1,8-naftiridinona e usos dos mesmos |
EP3654978A4 (en) * | 2017-07-18 | 2021-03-31 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSIN ANTAGONISTS |
KR102636384B1 (ko) | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
CN109651358B (zh) * | 2017-10-11 | 2023-04-07 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
JP2021503478A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | 組み合わせ治療 |
JP2021509009A (ja) | 2017-11-30 | 2021-03-18 | ノバルティス アーゲー | Bcmaターゲティングキメラ抗原受容体及びその使用 |
JP2021512959A (ja) | 2018-02-06 | 2021-05-20 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. | ピラゾロ[1,5−a][1,3,5]トリアジン−2−アミン誘導体、その製造法、およびその医薬用途 |
CN111989313A (zh) * | 2018-02-15 | 2020-11-24 | 杭州阿诺生物医药科技有限公司 | A2a和/或a2b受体拮抗剂 |
CN111440148B (zh) * | 2018-02-15 | 2021-07-30 | 杭州阿诺生物医药科技有限公司 | 一种腺苷受体拮抗剂的制备方法 |
IL301295A (en) | 2018-03-14 | 2023-05-01 | Surface Oncology Inc | Antibodies that bind CD39 and uses thereof |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
CR20200571A (es) | 2018-06-01 | 2021-01-18 | Novartis Ag | Moléculas de únion contra bcma y usos de las mismas |
CN110655509B (zh) * | 2018-06-29 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020011220A1 (zh) * | 2018-07-12 | 2020-01-16 | 江苏恒瑞医药股份有限公司 | 杂芳基类衍生物、其制备方法及其在医药上的应用 |
WO2020011245A1 (zh) * | 2018-07-13 | 2020-01-16 | 江苏恒瑞医药股份有限公司 | 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法 |
BE1026612B1 (fr) | 2018-09-27 | 2020-07-02 | Iteos Therapeutics S A | Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine |
JP2022509388A (ja) * | 2018-10-24 | 2022-01-20 | リードエックスプロ アーゲー | 官能化されたアミノトリアジン |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
CN111377873B (zh) * | 2018-12-28 | 2023-03-28 | 四川科伦博泰生物医药股份有限公司 | 氨基嘧啶化合物及其制备方法和用途 |
WO2020135195A1 (zh) | 2018-12-28 | 2020-07-02 | 四川科伦博泰生物医药股份有限公司 | 氨基吡啶类化合物及其制备方法和用途 |
CN113166119B (zh) * | 2018-12-28 | 2024-01-05 | 四川科伦博泰生物医药股份有限公司 | 取代芳基化合物及其制备方法和用途 |
US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
MX2021008650A (es) | 2019-01-18 | 2021-11-03 | Nuvation Bio Inc | Compuestos heterociclicos como antagonistas de adenosina. |
CN114007611A (zh) * | 2019-02-04 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
JP2022519312A (ja) * | 2019-02-05 | 2022-03-22 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
KR20210135241A (ko) * | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
CN114007612A (zh) * | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
KR20210135507A (ko) | 2019-02-06 | 2021-11-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CA3124935A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN112500416B (zh) | 2019-07-30 | 2021-12-17 | 厦门宝太生物科技股份有限公司 | 一种吡唑并三嗪类化合物中间体的制备方法 |
CN112625050B (zh) | 2019-07-30 | 2021-10-01 | 杭州阿诺生物医药科技有限公司 | 一种a2a和/或a2b受体抑制剂的制备方法 |
WO2021055329A1 (en) | 2019-09-16 | 2021-03-25 | Surface Oncology, Inc. | Anti-cd39 antibody compositions and methods |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
US20210115127A1 (en) | 2019-09-25 | 2021-04-22 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
WO2021071984A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
EP4069199B1 (en) * | 2019-12-02 | 2024-01-17 | Astrazeneca AB | Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
JPWO2021193982A1 (it) * | 2020-03-27 | 2021-09-30 | ||
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
KR20230048106A (ko) * | 2020-08-05 | 2023-04-10 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 조성물 |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
CA3199909A1 (en) * | 2020-11-23 | 2022-05-27 | Steven HOCHWALD | Compounds and methods to target glucose-stimulated phosphohistidine signaling and esophageal cancer growth |
JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗cd73及び抗entpd2抗体のための投与方式並びにその使用 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CN114113628A (zh) * | 2021-11-08 | 2022-03-01 | 华东师范大学 | 多巴胺d2受体在嗅觉外周调控及制备治疗嗅觉异常药物中的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4008232A (en) | 1975-06-23 | 1977-02-15 | Eli Lilly And Company | 3-Amino-5,6-diaryl-1,2,4-triazines |
CA1128507A (en) | 1977-05-17 | 1982-07-27 | James M. Gullo | Pharmacologically active substituted 1,2,4-triazines |
FR2485531A1 (fr) | 1980-06-25 | 1981-12-31 | Fabre Sa Pierre | Nouveaux n-oxydes de diaryl-5,6 as triazines 1-2-4, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
US4513135A (en) | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
JPH06501926A (ja) | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | 複素環式化合物 |
CO5210943A1 (es) | 1999-05-04 | 2002-10-30 | Novartis Ag | Compuestos plaguicidas derivados de triazina, composiciones para el control de plagas que comprenden dicho compuesto y cuando menos un auxiliar y metodos para controlar plagas |
US6555545B2 (en) | 2000-02-10 | 2003-04-29 | New York University | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
TWI316055B (it) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
TWI301834B (en) * | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
ATE466580T1 (de) | 2002-03-15 | 2010-05-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
BR0317436A (pt) | 2002-12-19 | 2005-11-16 | Schering Corp | Usos de antagonistas do receptor a2a de adenosina |
GB0300783D0 (en) | 2003-01-14 | 2003-02-12 | Btg Int Ltd | Treatment of neurodegenerative conditions |
WO2005012286A1 (en) * | 2003-07-25 | 2005-02-10 | Amgen Inc. | Substituted pyridones and pyrimidinones with antiinflammatory properties |
JP2005123160A (ja) | 2003-09-22 | 2005-05-12 | Nissan Motor Co Ltd | 燃料電池用セパレータ、燃料電池スタック及び燃料電池用セパレータの製造方法並びに燃料電池車両 |
CN1871231A (zh) * | 2003-10-27 | 2006-11-29 | 安斯泰来制药有限公司 | 吡嗪衍生物及其医药用途 |
BRPI0415863A (pt) * | 2003-10-27 | 2007-01-09 | Astellas Pharma Inc | derivados pirazina e seus usos farmacêuticos |
FR2869906B1 (fr) | 2004-05-05 | 2006-08-11 | Fabre Pierre Dermo Cosmetique | Derives monomeriques de 5,6-diphenyl-1,2,4-triazine et leurs utilisations |
EP1753429A1 (en) | 2004-05-28 | 2007-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
JP2008503464A (ja) | 2004-06-17 | 2008-02-07 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 習慣性行動の1つ以上の構成要素の改善のためのアデノシンa2aレセプターの拮抗 |
WO2006051311A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
CA2606288A1 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
US7851478B2 (en) | 2005-06-07 | 2010-12-14 | Kyowa Hakko Kirin Co., Ltd. | Agent for preventing and/or treating movement disorder |
ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
CN101460479A (zh) * | 2006-04-12 | 2009-06-17 | 巴斯夫欧洲公司 | 用作杀真菌剂的3-(吡啶-2-基)-[1,2,4]-三嗪 |
GB0800741D0 (en) * | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
DK2531492T3 (en) | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-amine derivatives |
-
2011
- 2011-02-07 DK DK11704571.6T patent/DK2531492T3/en active
- 2011-02-07 BR BR112012019540-9A patent/BR112012019540B1/pt active IP Right Grant
- 2011-02-07 ES ES11704571.6T patent/ES2579949T3/es active Active
- 2011-02-07 PT PT117045716T patent/PT2531492T/pt unknown
- 2011-02-07 WO PCT/EP2011/051755 patent/WO2011095625A1/en active Application Filing
- 2011-02-07 SG SG2012057436A patent/SG183146A1/en unknown
- 2011-02-07 AU AU2011212430A patent/AU2011212430B2/en active Active
- 2011-02-07 SI SI201130846A patent/SI2531492T1/sl unknown
- 2011-02-07 MX MX2012009073A patent/MX352415B/es active IP Right Grant
- 2011-02-07 KR KR1020127023230A patent/KR101838093B1/ko active IP Right Grant
- 2011-02-07 JP JP2012551647A patent/JP5914361B2/ja active Active
- 2011-02-07 CA CA2789279A patent/CA2789279C/en active Active
- 2011-02-07 EP EP11704571.6A patent/EP2531492B1/en active Active
- 2011-02-07 US US13/576,798 patent/US8809525B2/en active Active
- 2011-02-07 HU HUE11704571A patent/HUE028640T2/en unknown
- 2011-02-07 KR KR1020187006509A patent/KR101993867B1/ko active IP Right Grant
- 2011-02-07 MY MYPI2012003522A patent/MY180024A/en unknown
- 2011-02-07 PL PL11704571.6T patent/PL2531492T3/pl unknown
- 2011-02-07 RU RU2012137779A patent/RU2625791C2/ru active
- 2011-02-07 CN CN201180017840.3A patent/CN102822150B/zh active Active
-
2012
- 2012-07-29 IL IL221160A patent/IL221160A/en active IP Right Grant
- 2012-08-01 ZA ZA2012/05788A patent/ZA201205788B/en unknown
-
2014
- 2014-07-02 US US14/322,505 patent/US9249130B2/en active Active
-
2015
- 2015-12-21 US US14/976,738 patent/US20160175314A1/en not_active Abandoned
-
2016
- 2016-06-09 HR HRP20160636TT patent/HRP20160636T1/hr unknown
- 2016-06-23 SM SM201600198T patent/SMT201600198B/it unknown
- 2016-06-23 CY CY20161100573T patent/CY1117780T1/el unknown
- 2016-11-04 US US15/344,048 patent/US10112923B2/en active Active
-
2018
- 2018-10-16 US US16/161,409 patent/US10988455B2/en active Active
-
2021
- 2021-04-23 US US17/239,137 patent/US20230021177A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201600198B (it) | Derivati di 1,2,4-triazina-4-ammina | |
FR17C1040I2 (fr) | Derive antiviraux de 2,5-dibenzimidazol-5-yl-1-phenyl-pyrrolidine | |
SMT201600298B (it) | Derivati n3-sostituiti-n1-solfonil-5- fluoropirimidinone | |
SMT201600350B (it) | Composizioni farmaceutiche | |
SMT201500270B (it) | Derivati di pirrolotriazinone come inibitori di pi3k | |
SMT201600205B (it) | DERIVATI BENZOTIOFENICI SOSTITUITI CON PIPERAZINA COME AGENTI ANTlPSICOTICI | |
DK2590974T3 (da) | Tetrahydropyridopyrimidinderivater | |
DK2640893T4 (da) | Sammensætninger | |
CO6890099A2 (es) | Nuevos derivados dihidroquinolina-2-ona | |
DK3246018T3 (da) | Farmaceutisk sammensætning | |
ECSP12011999A (es) | Derivados benzamida sustituidos | |
SMT201600076B (it) | Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo | |
EE201300005A (et) | Ravimkoostis | |
SMT201400080B (it) | Derivati di pirazinoossazepina | |
DK3070091T3 (da) | Benzodioxolderivater som phosphodiesterasehæmmere | |
SMT201600405B (it) | Derivati di arilalchilamminocarbossammide fluorurati | |
CO6960557A2 (es) | Derivados de 2-yodo-imidazol | |
CO6801722A2 (es) | Composiciones farmacéuticas | |
SMT201500166B (it) | Derivato di 1,2,4-triazolone | |
SMT201500113B (it) | Processp per preparare derivati di alfa-carbossammide | |
BR112012028007A2 (pt) | composição aquosa | |
ITTO20110268A1 (it) | Composizione di maquillage. | |
SMT201500067B (it) | Derivati di acilbenzene | |
BR112012029461A2 (pt) | composição farmacêutica contendo solifenacina | |
IT1400964B1 (it) | Procedimento per la preparazione di derivati pteridinici |